Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E16.84 EPS (ttm)19.66 Insider Own0.10% Shs Outstand207.10M Perf Week-3.26%
Market Cap68.54B Forward P/E12.10 EPS next Y27.34 Insider Trans29.36% Shs Float200.65M Perf Month-2.83%
Income4.14B PEG2.15 EPS next Q6.78 Inst Own91.70% Short Float1.54% Perf Quarter-6.26%
Sales12.87B P/S5.32 EPS this Y3.00% Inst Trans0.05% Short Ratio2.24 Perf Half Y25.78%
Book/sh59.20 P/B5.59 EPS next Y8.15% ROA12.30% Target Price392.44 Perf Year-0.71%
Cash/sh15.57 P/C21.26 EPS next 5Y7.82% ROE22.90% 52W Range249.17 - 388.67 Perf YTD3.88%
Dividend- P/FCF14.71 EPS past 5Y24.80% ROI21.90% 52W High-14.72% Beta0.91
Dividend %- Quick Ratio2.10 Sales past 5Y17.30% Gross Margin86.40% 52W Low33.03% ATR7.97
Employees7300 Current Ratio2.40 Sales Q/Q9.00% Oper. Margin45.60% RSI (14)40.19 Volatility2.74% 2.28%
OptionableYes Debt/Eq0.48 EPS Q/Q2.80% Profit Margin23.10% Rel Volume0.45 Prev Close330.94
ShortableYes LT Debt/Eq0.48 EarningsOct 23 BMO Payout0.00% Avg Volume1.38M Price331.46
Recom1.90 SMA20-3.41% SMA50-3.56% SMA2005.77% Volume517,898 Change0.16%
Oct-08-18Reiterated Citigroup Buy $483 → $470
Oct-01-18Resumed Cantor Fitzgerald Overweight $400
Aug-07-18Resumed Stifel Buy $394
Jul-25-18Reiterated SunTrust Buy $321 → $392
Jul-10-18Downgrade Robert W. Baird Outperform → Neutral
Jul-06-18Upgrade Citigroup Neutral → Buy
May-31-18Upgrade Canaccord Genuity Hold → Buy $350 → $335
Apr-25-18Upgrade Robert W. Baird Neutral → Outperform
Apr-05-18Downgrade Barclays Overweight → Equal Weight $395 → $295
Feb-16-18Downgrade Argus Buy → Hold
Feb-05-18Reiterated Mizuho Buy $400 → $433
Jan-26-18Reiterated H.C. Wainwright Buy $340 → $363
Jan-24-18Reiterated Canaccord Genuity Hold $340 → $350
Jan-17-18Reiterated Canaccord Genuity Hold $340 → $350
Dec-22-17Reiterated Nomura Buy $355 → $420
Dec-20-17Upgrade Credit Suisse Neutral → Outperform
Oct-27-17Initiated Canaccord Genuity Hold $340
Oct-25-17Reiterated RBC Capital Mkts Sector Perform $315 → $313
Oct-24-17Initiated Guggenheim Buy $402
Oct-23-17Resumed Piper Jaffray Overweight $390
Oct-11-18 08:21AM  The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC Zacks
07:30AM  Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis GlobeNewswire
Oct-10-18 02:12PM  Top Analyst Reports for Altria, U.S. Bancorp & Biogen Zacks
10:18AM  Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status Zacks
Oct-08-18 04:05PM  Best Mutual Funds Buying CVS, Biogen, Lowe's And These Other Top Stocks Investor's Business Daily
Oct-06-18 07:30AM  New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy GlobeNewswire
Oct-05-18 06:15AM  Ex-Biogen employee with Parkinson's sues for discrimination American City Business Journals
Oct-04-18 07:32AM  PRESS DIGEST- Canada - Oct. 4 Reuters
Oct-03-18 07:30AM  Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinsons Disease and Movement Disorders (MDS) GlobeNewswire
02:06AM  With Hemlibra, Roche seeks to break into tight hemophilia circle Reuters
Oct-02-18 01:00PM  6 Health Care Stocks Poised For Healthy Gains Investopedia
07:30AM  Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care GlobeNewswire
Sep-28-18 01:44PM  Health care is having its best quarter in five years, and one winner is set to keep surging CNBC
Sep-26-18 02:11PM  US STOCKS-Wall Street extends gains after Fed rate hike Reuters
Sep-24-18 04:06PM  Can Biogen Continue to Be a Top Performer in the Biotech Space?
03:07PM  Does Biogen Incs (NASDAQ:BIIB) PE Ratio Warrant A Buy? Simply Wall St.
Sep-22-18 12:35AM  U.S. Probes Drugmakers Over Free Services The Wall Street Journal
Sep-21-18 03:23PM  U.S. Probes Drugmakers Over Free Services The Wall Street Journal
11:30AM  Biogen Seen Rising 15% On Brighter Outlook Investopedia
10:21AM  3 Drug/Biotech Stocks in Focus on World Alzheimer's Day Zacks
08:13AM  The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works Zacks
Sep-20-18 10:48AM  Top Research Reports for Wells Fargo, Schlumberger & Biogen Zacks
Sep-18-18 01:42PM  MARKETS: Wall Street loves US stocks, especially health care and industrials, EMs are nearing a buy Yahoo Finance Video
Sep-17-18 06:13PM  3 High-Quality Biotech Companies for 4th Quarter
10:09AM  Better Buy: Celgene Corp. vs. Biogen Motley Fool
Sep-13-18 08:53AM  Better Buy: Gilead Sciences, Inc. vs. Biogen Motley Fool
Sep-05-18 04:44PM  Biogen Begins Phase III Study on Ischemic Stroke Candidate Zacks
Sep-04-18 07:30AM  Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction GlobeNewswire
05:36AM  What you missed on your summer vacation in Mass. biotech news American City Business Journals
Aug-31-18 05:35PM  Biotech Fund Flows, Including ETF Activity, Remain a Driver to Watch ETF Trends
Aug-29-18 07:54AM  The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent Benzinga
Aug-28-18 07:30AM  Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimers Disease Treatment Aducanumab GlobeNewswire
Aug-27-18 01:12PM  Gene Editing is a Major Technology to Watch InvestorPlace
Aug-23-18 11:02AM  Biogen (BIIB) Down 10.1% Since Last Earnings Report: Can It Rebound? Zacks
Aug-22-18 08:17AM  3 Terrible Stocks for Retirees Motley Fool
Aug-17-18 10:05AM  Is Biogen (BIIB) Outperforming Other Medical Stocks This Year? Zacks
Aug-16-18 09:07AM  Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children Zacks
Aug-15-18 06:20AM  Express Scripts staking out million-dollar gene therapies Reuters
Aug-14-18 05:26PM  Bridgewater adds Alibaba, Amazon, Baidu, keeps large gold holdings MarketWatch
Aug-13-18 07:08PM  Biogen's pricey muscle drug Spinraza too costly for Britain Reuters
08:11AM  Theres new evidence that the dominant approach to Alzheimers may be completely wrong MarketWatch
Aug-11-18 02:30PM  Why Biogen's Stock Ripped Higher in July Motley Fool
Aug-10-18 02:00PM  4 Biotech Stocks That May Fall By as Much as 13% Investopedia
01:56PM  Biotech ETFs in Focus on String of Q2 Earnings Beat Zacks
Aug-09-18 01:29PM  Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript Motley Fool
06:00AM  What Separates Primecap Odyssey Growth From the Rest? Morningstar
Aug-07-18 02:26PM  Stifel Buys Back Into Biogen, Sees Upside In Alzheimer's Candidate Benzinga
01:51PM  Stifel: Biogen can rally to $394 CNBC Videos
Aug-06-18 09:37PM  5 Stocks That Should Start Paying Dividends Kiplinger
08:58AM  S&P 500 Posts 5th Straight Weekly Gain: 5 Great Picks Zacks
Aug-03-18 05:50PM  FOCUS-Eisai/Biogen to advance Alzheimer's drug, provide fresh hope Reuters
05:34PM  Edited Transcript of BIIB earnings conference call or presentation 24-Jul-18 12:00pm GMT Thomson Reuters StreetEvents
02:46PM  Avoid Treating Biogen Like a Speculative Drug Stock InvestorPlace
07:51AM featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM Zacks
07:22AM  Biogen's stock gets a boost from new $3.5 billion stock repurchase program MarketWatch
Aug-02-18 12:55PM  Adding Biotech ETFs to Your Portfolio Investopedia
09:27AM  5 Cheap PEG Stocks Suitable for GARP Investors Zacks
Aug-01-18 12:18PM  Is a Beat in Store for Ionis (IONS) This Earnings Season? Zacks
09:34AM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit Zacks
06:26AM  The Zacks Analyst Blog Highlights: Comcast, United Technologies, Biogen, Mondelez and Valero Zacks
Jul-31-18 11:12AM  Top Analyst Reports for Comcast, United Technologies & Biogen Zacks
09:30AM  Is Biogen (BIIB) Outperforming Other Medical Stocks This Year? Zacks
07:15AM  Free Stock Performance Review on Biogen and Three Additional Biotech Stocks ACCESSWIRE
06:33AM  Better Buy: Biogen Inc. vs. Gilead Sciences, Inc. Motley Fool
Jul-30-18 09:49AM  Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT Zacks
07:35AM  New Research Coverage Highlights Texas Instruments, Biogen, Sanchez Energy, Amazon, Sirius XM, and JPMorgan Chase Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
05:43AM  Fired Biogen employee sues company for retaliation American City Business Journals
Jul-27-18 11:53AM  Collaborations Help Alkermes Flip to Profitability Motley Fool
10:51AM  Alzheimer's Cure Search Leads to a Crash, Raises More Questions Bloomberg
07:59AM  Big Swings in Biogen Make It Hard to Take New Positions
Jul-26-18 07:49PM  [$$] Caution Still Needed on Biogen Alzheimers Bounty The Wall Street Journal -10.18%
04:49PM  [$$] Caution Still Needed on Biogen Alzheimer's Bounty The Wall Street Journal
04:48PM  Why Biogen's Stock Is Slumping Today Motley Fool
03:43PM  Biogen Plummets as Alzheimer Drug Shows Little Efficacy in Trial
11:07AM  Biogen, Eisai sink as much-awaited Alzheimers results raise more questions CNBC
09:03AM  Alzheimer's Study Lacks Shock and Awe Biogen Investors Sought Bloomberg
08:41AM  Biogen Sinks After Alzheimer's Data Leaves Analysts With Questions Bloomberg
08:40AM  Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold Benzinga
07:32AM  Biogen CEO: Alzheimer's drug shows positive results CNBC Videos
07:31AM  Biogen shares drop despite positive Alzheimer's drug resu... CNBC Videos
Jul-25-18 08:15PM  [$$] Alzheimers Drug Shows Benefit, But Some Experts Say More Testing Needed The Wall Street Journal
06:54PM  Biogens Results Leave the Alzheimers Puzzle Unsolved Bloomberg
06:46PM  Biogen Shares Plummet Despite Alzheimer's Drug Exceeding Expectations
06:44PM  [$$] Alzheimer's Drug Shows Benefit The Wall Street Journal
06:20PM  Biogen/Eisai Alzheimer's drug cuts cognitive decline 30 pct -study Reuters
05:34PM  Biogen says Alzheimer's drug slowed disease, but shares tumble on skepticism American City Business Journals
05:12PM  Biogen shares down 9% after Alzheimer's trial results MarketWatch
05:11PM  Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018 GlobeNewswire
04:31PM  Biogens Alzheimers Drug Data Encouraging, Not Shock and Awe Bloomberg
04:30PM  Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimers Disease at Alzheimers Association International Conference (AAIC) 2018 GlobeNewswire
04:25PM  Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018 PR Newswire
04:25PM  Biogen and Eisai say Alzheimers treatment slowed disease progression, backing amyloid theory CNBC
03:58PM  Biogen alzheimer's drug shows positive results CNBC Videos
03:21PM  Biogen Posts Solid Earnings as the Biotech Waits for Clinical Trial Data Motley Fool
02:59PM  Biogen Shares Gain On Midstage Results For Alzheimer's Candidate Benzinga
02:52PM  Biogen and Eisai to reveal results of Alzheimer's drug tr... CNBC Videos
11:24AM  Biogen shares rise 4% before release of Alzheimer's disease trial results MarketWatch
11:12AM  Why Every Investor Should Hold Shares of Biogen Stock InvestorPlace
10:49AM  Company News For Jul 25, 2018 Zacks
10:36AM  Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018 GlobeNewswire
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. In addition, the company is developing BAN2401, which has completed Phase II clinical trial for the treatment of Alzheimer's disease, as well as Elenbecestat that is in Phase III clinical trial for treatment of early Alzheimer's disease. The company's Phase II clinical trial products comprise Opicinumab for MS; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild Alzheimer's disease. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ehlers Michael DEVP, Research and DevelopmentSep 26Sale350.001,000350,0004,281Sep 27 04:16 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0026201,122Aug 03 04:14 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,38405,897Jun 05 04:31 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,687010,118May 04 06:09 PM
DENNER ALEXANDER JDirectorApr 25Buy269.9148,00012,955,680461,858Apr 27 07:48 AM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0053204,539Mar 05 04:41 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 27Sale290.8325975,3256,553Feb 28 05:39 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 23Option Exercise0.0046707,020Feb 27 06:25 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.009204,772Feb 27 06:24 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 23Option Exercise0.00857025,225Feb 27 06:22 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 23Sale293.44908266,4446,553Feb 27 06:25 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 22Option Exercise0.0019404,738Feb 26 04:11 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,63508,188Feb 26 04:12 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 22Option Exercise0.001,635025,095Feb 26 04:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 20Sale292.00743216,9566,553Feb 21 04:10 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,354010,233Feb 20 04:27 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,33909,186Feb 20 04:25 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,47204,854Feb 20 04:23 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,71205,407Feb 20 04:20 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 15Option Exercise0.0016104,600Feb 20 04:18 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 15Option Exercise0.001,712023,970Feb 20 04:17 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Sale298.851,294386,7127,296Feb 20 08:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.002,01208,565Feb 14 06:37 PM
PANGIA ROBERT WDirectorJan 09Option Exercise57.835,832337,26523,539Jan 10 05:28 PM
PANGIA ROBERT WDirectorJan 09Sale329.655,8321,922,51917,707Jan 10 05:28 PM
Vounatsos MichelChief Executive OfficerDec 29Buy320.55780250,0294,879Jan 02 04:21 PM
DENNER ALEXANDER JDirectorNov 29Buy319.8410,0003,198,400413,858Nov 30 07:30 AM
DENNER ALEXANDER JDirectorNov 28Buy316.1220,0006,322,400403,858Nov 30 07:30 AM